NOWDiagnostics®

Our lab – at the tip of your finger

INTRODUCING

ADEXUSDx® COVID-19 Total Antibody Rapid Test

Featuring Touch-to-Test Technology

Sample is applied directly to the tip of the test

The ADEXUSDx® COVID-19 Test is a rapid serology test that detects total antibodies to SARS-CoV-2. It provides in-field, lab accurate results within 15 minutes, using as little as a drop of blood.

SIMPLE

- **NO** buffers or external reagents needed
- **NO** lab equipment
- **NO** in demand ancillary items
- **NO** refrigeration

ACCURATE

- Highly sensitive and specific
- Detects total antibody (IgG, IgM and IgA)
- Used to identify adaptive immune response (indicating recent or prior infection)



Administering Test*

TRANSFER DEVICE METHOD
(Emergency Use Authorized)

1. Collect 40 µL of sample using a liquid transfer device.

2. Apply sample to the test.



3. Set timer for 15 minutes and read result.

FINGER STICK METHOD

1. Perform finger stick.



2. Touch the drop of blood to the tip of the test.



3. Set timer for 15 minutes and read result.

INTERPRETATION OF RESULTS

A positive result has TWO LINES, one at the “C” (Control Line) and one at the “T” (Test Line). The intensity of the lines may vary. Look carefully as **lines might be faint.**



Positive Result | Negative Result | Invalid Result | Invalid Result

* For complete instructions, refer to the Product Insert before administering the test.

Visit **C19Development.com** for more information.

Description	Quantity	Catalog Number
ADEXUSDx® COVID-19 Test, Box	25	8075-25
ADEXUSDx® COVID-19 Test, Box	50	8075-50
ADEXUSDx® COVID-19 Test, Case	1000	8075-1000
ADEXUSDx® COVID-19 Control Set, Box	1	475.002

MADE IN USA

The ADEXUSDx® COVID-19 Test has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories. It is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.